Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.45 |
| ▸ | CCR8 | P51685 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16203112 | 0.90 | FFAR1 (0.53) | FFAR1HRH3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL16203110 | 0.89 | FFAR1 (0.52) | FFAR1HRH3FAAH | |
| SCHEMBL16203115 | 0.89 | FFAR1 (0.52) | FFAR1HRH3FAAH | |
| SCHEMBL1130311 | 0.86 | HRH3 (0.54) | FFAR1HRH3SMN1; SMN2CYP2A6CTSL | |
| SCHEMBL1138657 | 0.86 | HRH3 (0.54) | FFAR1HRH3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4472579 | 0.86 | HRH3 (0.54) | FFAR1HRH3SMN1; SMN2CYP2A6CTSL | |
| SCHEMBL5266894 | 0.86 | HRH3 (0.54) | FFAR1HRH3SMN1; SMN2CYP2A6HIF1A | |
| SCHEMBL1139044 | 0.86 | HRH3 (0.57) | FFAR1HRH3SMN1; SMN2CYP2A6CTSL | |
| SCHEMBL17779983 | 0.85 | FFAR1 (0.58) | FFAR1HRH3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL16595254 | 0.83 | HRH3 (0.51) | FFAR1HRH3CYP2A6CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148410-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148410-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | GLI1, SHH, HRAS | FFAR1 1847/4885HRH3 1637/4885SMN1; SMN2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.